GH Research Reports Q2 2025 Results: Net Loss Narrows to $9.3M, EPS Improves to $0.15 Loss

Reuters08-07
GH Research Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Loss Narrows to $9.<a href="https://laohu8.com/S/MMM">3M</a>, EPS Improves to $0.15 Loss

GH Research plc, a clinical-stage biopharmaceutical company, has released its financial results for the second quarter of 2025. The company reported a net loss of $9.3 million for the quarter ended June 30, 2025, compared to a net loss of $10.4 million for the same quarter in 2024. General and administrative expenses rose to $5.7 million from $3.5 million in the previous year, primarily due to increased professional fees and employee expenses. Research and development expenses decreased to $9.0 million from $9.8 million, attributed to reduced expenses in clinical development activities and a research and development tax credit, partially offset by higher technical development and employee expenses. As of June 30, 2025, GH Research reported cash, cash equivalents, and marketable securities totaling $308.7 million, up from $182.6 million as of December 31, 2024. The increase was bolstered by gross proceeds of $150.0 million from a public offering in Q1 2025. In terms of business updates, GH Research announced that its engagement with the U.S. Food and Drug Administration (FDA) regarding the clinical hold on its Investigational New Drug Application $(IND.AU)$ for GH001 is ongoing, with one hold topic remaining. The company anticipates initiating its global pivotal program in 2026. GH Research also highlighted that its Open-Label Extension analysis confirms a 73% remission rate at six months with infrequent treatment visits and no psychotherapy, with the treatment being well tolerated and no serious adverse events reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9508066-en) on August 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment